Corporate Vision Issue 10 2018

CORPORATE VISION / Issue 10 2018 35 , 1809CV35 NLS-1 Pharma is a clinical-stage drug development company. Recently, the firm’s CEO, Alex Zwyer found success in corporate Vision’s 2018 Corporate Excellence Awards where they received the accoladeMost Influential CEOof the Year 2018 – Switzerland. On the back of this win, we profiled the firmand spoke to Alex to discovermore about the award-winning services NLS-1 Pharma provides. Successful Collaboration NLS-1 Pharma AG (NLS) is a Swiss- based clinical-stage biotechnology company focused on developing innovative and more effective, safe treatments for ADHD and other CNS disorders. Behavioural disorders like Attention Deficit Hyperactivity Disorder (ADHD) affects children and adults and impacts negatively across all aspects of their life, from schooling to work to relationships. The US Center for Disease Control and Prevention (CDC) says that 11% of American children between the ages of four to 11 have some form of ADHD. Moreover, those figures look set to rise. Treatment options are important and can significantly affect the quality of life for children and adults affected by this condition. This dilemma is why a company like NLS matters. Going into greater detail about ADHD, Alex begins by explaining the stimulants which are highly effective for the condition. “ADHD is one of the most prevalent psychiatric disorders in children and adults worldwide. First-line pharmacological management is with psychostimulants, such as methylphenidate and amphetamine, which are Schedule II controlled substances (C2, per the US Drug Enforcement Agency [DEA]). While C2 stimulants are highly effective for ADHD, stimulants are misused recreationally with both diversion and abuse being common problems. “Furthermore, not all individuals respond optimally to or tolerate C2 stimulants because of adverse events. Non-stimulants (e.g., atomoxetine and alpha-2 agonists such as long-acting clonidine and guanfacine) are Food and Drug Administration (FDA)-approved for ADHD, but efficacy, overall, is not as robust as with C2 stimulants. Moreover, the tolerability profile is not necessarily superior to stimulants. The ‘holy grail’ in ADHD is yet to be developed: a therapeutic agent as effective as a stimulant and at the same time as safe as a non-stimulant.” When discussing the internal culture at NLS-1, Alex highlights how each member of the team are equipped to provide the best possible service to their clients, as well explaining to us their approach to attracting the best talent to the company. “Here at NLS-1, we only work with the very best people in the ADHD space, most are top notch former top executive from leading ADHD companies. It is not secret that everybody wants to be on the winning team. Currently, NLS is perceived as a potential game- changer in the global ADHD space both commercially, as well as scientifically speaking.” Bringing the interview to a close, Alex signs off by revealing what developments he foresees within the industry, and how NLS-1 will adapt around these. “Looking ahead to what the future holds, MoA and clinical results with mazindol CR are both very exciting and could potentially pave the way for a game-changer in the ADHD space.” Name: Alex Zwyer, CEO Web Address: nlspharma.com Address: Switzerland Telephone: +41 41 6188000